The utility of α-synuclein as biofluid marker in neurodegenerative diseases: A systematic review of the literature

Anja Hviid Simonsen, Bea Kuiperij, Omar Ali El-Agnaf, Sebastian Engelborghs, Sanna Kaisa Herukka, Lucilla Parnetti, Irena Rektorova, Eugeen Vanmechelen, Elisabeth Kapaki, Marcel Verbeek, Brit Mollenhauer

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The discovery of α-synuclein (α-syn) as a major component of Lewy bodies, neuropathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies and of glial inclusions in multiple system atrophy initiated the investigation of α-syn as a biomarker in cerebrospinal fluid (CSF). Due to the involvement of the periphery in PD the quantification of α-syn in peripheral fluids such as serum, plasma and saliva has been investigated as well. We review how the development of multiple assays for the quantification of α-syn has yielded novel insights into the variety of α-syn species present in the different fluids; the optimal preanalytical conditions required for robust quantification and the potential clinical value of α-syn as biomarker. We also suggest future approaches to use of CSF α-syn in neurodegenerative diseases.

Original languageEnglish
Pages (from-to)19-34
Number of pages16
JournalBiomarkers in Medicine
Volume10
Issue number1
DOIs
Publication statusPublished - 1 Jan 2016

Fingerprint

Synucleins
Neurodegenerative diseases
Cerebrospinal fluid
Biomarkers
Neurodegenerative Diseases
Parkinson Disease
Cerebrospinal Fluid
Multiple System Atrophy
Lewy Bodies
Lewy Body Disease
Fluids
Saliva
Neuroglia
Assays
Plasmas
Serum

Keywords

  • biomarker
  • CSF
  • diagnosis
  • ELISA
  • Parkinson's disease
  • α-synuclein

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Drug Discovery
  • Medicine(all)

Cite this

The utility of α-synuclein as biofluid marker in neurodegenerative diseases : A systematic review of the literature. / Simonsen, Anja Hviid; Kuiperij, Bea; Ali El-Agnaf, Omar; Engelborghs, Sebastian; Herukka, Sanna Kaisa; Parnetti, Lucilla; Rektorova, Irena; Vanmechelen, Eugeen; Kapaki, Elisabeth; Verbeek, Marcel; Mollenhauer, Brit.

In: Biomarkers in Medicine, Vol. 10, No. 1, 01.01.2016, p. 19-34.

Research output: Contribution to journalArticle

Simonsen, AH, Kuiperij, B, Ali El-Agnaf, O, Engelborghs, S, Herukka, SK, Parnetti, L, Rektorova, I, Vanmechelen, E, Kapaki, E, Verbeek, M & Mollenhauer, B 2016, 'The utility of α-synuclein as biofluid marker in neurodegenerative diseases: A systematic review of the literature', Biomarkers in Medicine, vol. 10, no. 1, pp. 19-34. https://doi.org/10.2217/BMM.14.105
Simonsen, Anja Hviid ; Kuiperij, Bea ; Ali El-Agnaf, Omar ; Engelborghs, Sebastian ; Herukka, Sanna Kaisa ; Parnetti, Lucilla ; Rektorova, Irena ; Vanmechelen, Eugeen ; Kapaki, Elisabeth ; Verbeek, Marcel ; Mollenhauer, Brit. / The utility of α-synuclein as biofluid marker in neurodegenerative diseases : A systematic review of the literature. In: Biomarkers in Medicine. 2016 ; Vol. 10, No. 1. pp. 19-34.
@article{69e8b1a8728b452a805f33757c71fb0b,
title = "The utility of α-synuclein as biofluid marker in neurodegenerative diseases: A systematic review of the literature",
abstract = "The discovery of α-synuclein (α-syn) as a major component of Lewy bodies, neuropathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies and of glial inclusions in multiple system atrophy initiated the investigation of α-syn as a biomarker in cerebrospinal fluid (CSF). Due to the involvement of the periphery in PD the quantification of α-syn in peripheral fluids such as serum, plasma and saliva has been investigated as well. We review how the development of multiple assays for the quantification of α-syn has yielded novel insights into the variety of α-syn species present in the different fluids; the optimal preanalytical conditions required for robust quantification and the potential clinical value of α-syn as biomarker. We also suggest future approaches to use of CSF α-syn in neurodegenerative diseases.",
keywords = "biomarker, CSF, diagnosis, ELISA, Parkinson's disease, α-synuclein",
author = "Simonsen, {Anja Hviid} and Bea Kuiperij and {Ali El-Agnaf}, Omar and Sebastian Engelborghs and Herukka, {Sanna Kaisa} and Lucilla Parnetti and Irena Rektorova and Eugeen Vanmechelen and Elisabeth Kapaki and Marcel Verbeek and Brit Mollenhauer",
year = "2016",
month = "1",
day = "1",
doi = "10.2217/BMM.14.105",
language = "English",
volume = "10",
pages = "19--34",
journal = "Biomarkers in Medicine",
issn = "1752-0363",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - The utility of α-synuclein as biofluid marker in neurodegenerative diseases

T2 - A systematic review of the literature

AU - Simonsen, Anja Hviid

AU - Kuiperij, Bea

AU - Ali El-Agnaf, Omar

AU - Engelborghs, Sebastian

AU - Herukka, Sanna Kaisa

AU - Parnetti, Lucilla

AU - Rektorova, Irena

AU - Vanmechelen, Eugeen

AU - Kapaki, Elisabeth

AU - Verbeek, Marcel

AU - Mollenhauer, Brit

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The discovery of α-synuclein (α-syn) as a major component of Lewy bodies, neuropathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies and of glial inclusions in multiple system atrophy initiated the investigation of α-syn as a biomarker in cerebrospinal fluid (CSF). Due to the involvement of the periphery in PD the quantification of α-syn in peripheral fluids such as serum, plasma and saliva has been investigated as well. We review how the development of multiple assays for the quantification of α-syn has yielded novel insights into the variety of α-syn species present in the different fluids; the optimal preanalytical conditions required for robust quantification and the potential clinical value of α-syn as biomarker. We also suggest future approaches to use of CSF α-syn in neurodegenerative diseases.

AB - The discovery of α-synuclein (α-syn) as a major component of Lewy bodies, neuropathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies and of glial inclusions in multiple system atrophy initiated the investigation of α-syn as a biomarker in cerebrospinal fluid (CSF). Due to the involvement of the periphery in PD the quantification of α-syn in peripheral fluids such as serum, plasma and saliva has been investigated as well. We review how the development of multiple assays for the quantification of α-syn has yielded novel insights into the variety of α-syn species present in the different fluids; the optimal preanalytical conditions required for robust quantification and the potential clinical value of α-syn as biomarker. We also suggest future approaches to use of CSF α-syn in neurodegenerative diseases.

KW - biomarker

KW - CSF

KW - diagnosis

KW - ELISA

KW - Parkinson's disease

KW - α-synuclein

UR - http://www.scopus.com/inward/record.url?scp=84951806008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951806008&partnerID=8YFLogxK

U2 - 10.2217/BMM.14.105

DO - 10.2217/BMM.14.105

M3 - Article

C2 - 26314196

AN - SCOPUS:84951806008

VL - 10

SP - 19

EP - 34

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

SN - 1752-0363

IS - 1

ER -